THE WOODLANDS, Texas, Oct. 14, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be presenting initial Phase 1 clinical trial results for LX2931, an orally-delivered, small molecule drug candidate for the treatment of rheumatoid arthritis and other autoimmune conditions at the annual meeting of the American College of Rheumatology in San Francisco, California. LX2931 is one of four programs in human clinical trials as part of Lexicon's 10TO10 program. Lexicon also has two additional drug candidates in formal preclinical studies.
